Trial reportDiabetologia1998
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Trial report in Diabetologia, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02633488 (Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome
Who cites it
38 citing papers in PubMed, 176 citations in OpenAlex.
- The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma.British journal of clinical pharmacology · 2016Trial
- Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.Cardiovascular diabetology · 2010Trial
- Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability.American journal of physiology. Endocrinology and metabolism · 2006Trial
- Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.Diabetes care · 2005Trial
- The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly.The Journal of clinical endocrinology and metabolism · 2000Trial
- Correlation of Asymmetric Dimethylarginine With Podocytopathy Markers in Diabetic Kidney Disease Patients.International journal of nephrology and renovascular disease · 2024Article
- An oral glucose tolerance test does not affect cerebral blood flow: role of NOS.American journal of physiology. Regulatory, integrative and comparative physiology · 2023Article
- Role of flavonoids in controlling obesity: molecular targets and mechanisms.Frontiers in nutrition · 2023Review
- New insights into mechanisms of endothelial insulin resistance in type 2 diabetes.American journal of physiology. Heart and circulatory physiology · 2022Review
- Aortic Stiffness in L-NAME Treated C57Bl/6 Mice Displays a Shift From Early Endothelial Dysfunction to Late-Term Vascular Smooth Muscle Cell Dysfunction.Frontiers in physiology · 2022Article
- The SWELL1-LRRC8 complex regulates endothelial AKT-eNOS signaling and vascular function.eLife · 2021Article
- Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?Biomedicines · 2020Review
- Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015Review
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.Biochemical pharmacology · 2014Review
- Regulation of obesity and insulin resistance by nitric oxide.Free radical biology & medicine · 2014Review
- Antiobesogenic role of endothelial nitric oxide synthase.Vitamins and hormones · 2014Article
- Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications.American journal of physiology. Endocrinology and metabolism · 2013Review
- Symptomatic lipid storage in carriers for the PNPLA2 gene.European journal of human genetics : EJHG · 2013Article
- The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.Pflugers Archiv : European journal of physiology · 2013Review
- In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Diabetes care · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is associated with a decreased vasodilator response to insulin. Because insulin's vasodilator effect is nitric oxide dependent, this impairment may reflect endothelial dysfunction. Troglitazone, an insulin-sensitiser, might thus improve insulin-dependent and/or endothelium-dependent vascular function in insulin resistant obese subjects. For 8 weeks, fifteen obese subjects were treated with either 400 mg troglitazone once daily or placebo, in a randomised, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses (plethysmography) to intra-arterial administered acetylcholine and sodium nitroprusside; insulin sensitivity and insulin-induced vascular and neurohumoral responses (clamp); vasoconstrictor responses to NC-monomethyl-L-arginine (L-NMMA) during hyperinsulinaemia; and ambulatory 24-h blood pressure (ABPM). Baseline data (placebo) of obese subjects were compared with those obtained in lean control subjects. Obese subjects were insulin resistant compared with leans (whole-body glucose uptake: 26.8+/-3.0 vs. 53.9+/-4.3 [tmol kgl min-, p < 0.001). Troglitazone improved whole-body glucose uptake (to 31.9+/-3.3 micromol x kg(-1) x min(-1) , p=0.028), and forearm glucose uptake (from 1.09+/-0.54 to 2.31+/-0.69 micromol dL(-1) x min(-1), p=0.006). Insulin-induced vasodilatation was blunted in obese subjects (percent increase in forearm blood flow (FBF) in lean 66.5+/-23.0%, vs. 10.1+/-11.3% in obese, p=0.04), but did not improve during troglitazone. Vascular responses to acetylcholine, sodium nitroprusside and L-NMMA did not differ between the obese and lean group, nor between both treatment periods in the obese individuals. In conclusion, in insulin resistant obese subjects, endothelial vascular function is normal despite impaired vasodilator responses to insulin. Troglitazone improved insulin sensitivity but it had no effects on endothelium-dependent and -independent vascular responses. These data do not support an association between insulin resistance and endothelial function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.